Athersys (NASDAQ:ATHX) Coverage Initiated at StockNews.com

Equities researchers at StockNews.com assumed coverage on shares of Athersys (NASDAQ:ATHX) in a report released on Wednesday. The brokerage set a “hold” rating on the biopharmaceutical company’s stock.

Athersys Stock Performance

Athersys has a twelve month low of $0.01 and a twelve month high of $1.99. The company has a market cap of $833,000.00, a PE ratio of -0.01 and a beta of -0.90.

Athersys Company Profile

Athersys, Inc, a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions.